JNJ-26076713

Cat. No.:	HY-116030
CAS No.:	669076-03-3
Molecular Formula:	$C_{29}H_{38}N_4O_3$
Molecular Weight:	490.64
Target:	Integrin
Pathway:	Cytoskeleton
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	JNJ-26076713 is a potent and orally active alpha V integrin antagonist with IC_{50} values of 2.3 nM and 6.3 nM for alpha(V)beta(3) and alpha(V)beta(5), respectively. JNJ-26076713 inhibits retinal neovascularization[1].

IC_{50} & Target	αvβ3	αvβ5
	2.3 nM (IC_{50})	6.3 nM (IC_{50})

In Vitro

JNJ-26076713 (5-5000 nM) inhibits FGF2-induced HUVEC migration in a dose-dependent manner[1].

JNJ-26076713 (0.1, 1, and 10 μg) inhibits angiogenesis in the chick chorioallantoic membrane (CAM) model in a dose-dependent manner[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

JNJ-26076713 (30-120 mg/kg; i.g.; twice daily for 5 days; C57BL/6J mice with oxygen-induced retinopathy (OIR) model) inhibits retinal neovascularization in a dose-dependent manner[1].

JNJ-26076713 (60 mg/kg; i.g.; twice daily for 5 days; diabetic Long-Evans rats) inhibits the increase in retinal vascular permeability and leukostasis associated with diabetes[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57BL/6J mice with oxygen-induced retinopathy (OIR) model[1]
Dosage:	30, 60, and 120 mg/kg
Administration:	Oral gavage, twice daily for 5 days
Result:	Inhibited retinal neovascularization with 33, 43, and 67% inhibition of neovascularization at 30, 60, and 120 mg/kg, respectively.

Animal Model:	Diabetic Long-Evans rats[1]
Dosage:	60 mg/kg
Administration:	Oral gavage, twice daily for 5 days
Result:	Reduced leukocyte adhesion with 48% and inhibited retinal vascular permeability in

	streptozotocin diabetic rats.

REFERENCES

[1]. Santulli RJ, et, al. Studies with an orally bioavailable alpha V integrin antagonist in animal models of ocular vasculopathy: retinal neovascularization in mice and retinal vascular permeability in diabetic rats. J Pharmacol Exp Ther. 2008 Mar;324(3):894-901.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA